AI Executive Summary
AI-powered analysis of 10-Q filing content
Radnostix Inc. shows significant financial deterioration with revenue down 27% and net loss increasing over 700% year-over-year for the six-month period. The company faces negative working capital, declining cash reserves, and an unresolved FDA Official Action Indicated (OAI) status stemming from an April 2025 inspection at its Idaho Falls facility. Combined with a heavy mandatorily redeemable preferred stock obligation and rising related-party debt, these factors raise material concerns about near-term liquidity and operational stability.
Red Flags Detected (11)
Net loss increased from $273,479 to $2,230,083 (716% increase) for six months ended June 30, 2026
Revenue declined 27% for both quarterly and six-month periods (Q2: $2.67M vs $3.66M; H1: $5.05M vs $6.89M)
Cash and cash equivalents dropped from $1,695,158 to $1,196,492 (29% decline)
8 more red flags detected
Key Takeaways
Revenue and profitability have deteriorated substantially across all five reportable segments (Theranostics, Cobalt, Calibration & Reference, Medical Devices, Fluorine Products)
The company converted from positive to negative working capital within six months
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.